×
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
NYSE:PFE

Pfizer Price Target, Predictions & Analyst Ratings

$52.75
+1.11 (+2.15%)
(As of 07/6/2022 05:44 PM ET)
Add
Compare
Today's Range
$51.58
$52.96
50-Day Range
$46.53
$53.99
52-Week Range
$38.93
$61.71
Volume
21.30 million shs
Average Volume
19.73 million shs
Market Capitalization
$295.97 billion
P/E Ratio
12.10
Dividend Yield
3.10%
Price Target
$57.26

Pfizer (NYSE:PFE) Price Target and Consensus Rating (2022)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 18 Analyst Ratings

Consensus Analyst Price Target

$57.26
8.56% Upside
High Prediction$76.00
Average Prediction$57.26
Low Prediction$44.00
TypeCurrent
7/7/21 to 7/7/22
1 Month Ago
6/7/21 to 6/7/22
3 Months Ago
4/8/21 to 4/8/22
1 Year Ago
7/7/20 to 7/7/21
Consensus Rating
Moderate Buy
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
2 Buy rating(s)
Hold
9 Hold rating(s)
10 Hold rating(s)
10 Hold rating(s)
11 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$57.26$57.26$58.32$41.69
Predicted Upside8.56% Upside9.90% Upside11.09% Upside7.11% Upside
Get Pfizer Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PFE and its competitors with MarketBeat's FREE daily newsletter.


PFE Stock Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Stock Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerMedical CompaniesS&P 500
Consensus Rating Score
2.50
2.72
2.51
Consensus RatingModerate BuyBuyBuy
Predicted Upside8.56% Upside462.17% Upside31.96% Upside
News Sentiment RatingNeutral News
Positive News
Neutral News
MarketBeat
Community Rating
Outperform Votes
1454
71.27%
Underperform Votes
586
28.73%
Avg. Outperform Votes
167
67.07%
Avg. Underperform Votes
82
32.93%
Avg. Outperform Votes
839
69.05%
Avg. Underperform Votes
376
30.95%

Historical Pfizer Price Targets and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/28/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Schott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$57.00+12.51%
6/27/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$52.00+0.08%
5/27/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luisa Hector
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$50.00-7.25%
5/25/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Chris Shibutani
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$51.00-4.26%
5/23/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$55.00+4.82%
5/4/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$60.00 ➝ $55.00+11.58%
4/6/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageEqual Weight$55.00+4.78%
4/5/2022Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral$46.00 ➝ $57.00+11.90%
2/10/2022Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vamil Divan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Target$56.00 ➝ $55.00+6.86%
1/14/2022BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$60.00 ➝ $76.00+36.84%
1/5/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$59.00 ➝ $70.00+28.37%
1/3/2022Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$44.00 ➝ $65.00+13.80%
12/20/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$56.00 ➝ $70.00+15.95%
12/13/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Bristow Colin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$52.00 ➝ $60.00+13.68%
11/24/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Robyn Karnauskas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy$43.00 ➝ $58.00+13.44%
11/11/2021Independent Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tobias Gottschalt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$53.00+5.51%
11/5/2021Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Louise Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$60.00+23.43%
11/5/2021Benchmark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$29.00 ➝ $45.00-7.29%
7/29/2021Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Set Target$44.00+1.27%
2/3/2021DZ Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold ➝ Buy$41.00+17.11%
10/12/2020Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral$44.00 ➝ $39.00+6.01%
6/26/2020Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$18.50 ➝ $24.00-24.25%
2/27/2020Standpoint Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
11/6/2019Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold$41.30+10.06%
(Data available from 7/7/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












Pfizer Price Target - Frequently Asked Questions

What is Pfizer's consensus rating and price target?

According to the issued ratings of 18 analysts in the last year, the consensus rating for Pfizer stock is Moderate Buy based on the current 9 hold ratings and 9 buy ratings for PFE. The average twelve-month price prediction for Pfizer is $57.26 with a high price target of $76.00 and a low price target of $44.00. Learn more on PFE's analyst rating history.

Do Wall Street analysts like Pfizer more than its competitors?

Analysts like Pfizer stock less than the stock of other Medical companies. The consensus rating for Pfizer is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how PFE compares to other companies.

Do MarketBeat users like Pfizer more than its competitors?

MarketBeat users like Pfizer stock more than the stock of other Medical companies. 71.27% of MarketBeat users gave Pfizer an outperform vote while medical companies recieve an average of 66.80% outperform votes by MarketBeat users.

Does Pfizer's stock price have much upside?

According to analysts, Pfizer's stock has a predicted upside of 9.06% based on their 12-month price targets.

What analysts cover Pfizer?
This page (NYSE:PFE) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.